Amaç: Romatoid artrit (RA), patogenezinde genetik ve epigenetik faktörlerin etkili olduğu kronik inflamatuar bir hastalıktır. Orosomukoid-1 (ORM1), antiinflamatuar özelliğe sahip olan bir akut faz yanıt proteinidir ve yapılan çalışmalarda RA patogenezi ile ilişkili olduğu gösterilmiştir. Ancak hastalıktaki rolü tam olarak aydınlatılmamıştır. Bu çalışmada, RA hastalarında ve sağlıklı kontrollerde serum ORM1 düzeylerinin ve ORM1 gen promotörü metilasyonunun araştırılması amaçlandı. Gereç ve Yöntemler: Klinik olarak RA teşhisi olan 40 hasta ve 31 sağlıklı kontrol çalışmaya dâhil edildi. Tüm donörlere ait periferik kan örneklerindeki serum ORM1 seviyeleri ELISA yöntemi ile belirlendi. Aynı bireyler için kandan DNA izolasyonu yapıldı. Elde edilen DNA örneklerine bisülfit modifikasyonu yapıldı. ORM1 gen promotörü için tasarlanan metilasyon spesifik primerler kullanılarak, ORM1 geni promotör metilasyon profilleri, metilasyon spesifik polimeraz zincir reaksiyonu metodu ile belirlendi. Bulgular: Serum ORM1 seviyesinin, kontrol grubunda hasta grubuna kıyasla yaklaşık 3,2 kat yüksek olduğu gözlendi (p
Anahtar Kelimeler: Arthritis, rheumatoid; orosomucoid; DNA methylation
Objective: Rheumatoid arthritis (RA) is a chronic inflammatory disease, and genetic and environmental factors are wellknown causes. Orosomucoid-1 (ORM1) is an acute phase response protein with anti-inflammatory properties and associated with the RA pathogenesis. However, its role in RA has not been fully known. In this study, we aimed to investigate serum ORM1 levels and methylation of ORM1 gene promoter in RA patients and healthy controls. Material and Methods: The study group consisted of 40 RA patients and 31 healthy controls. Serum levels of ORM1 in RA patients and healthy controls were determined by using the ELISA method. After genomic DNA was isolated from blood samples, DNA samples were modified with bisulfite. Promoter methylation of ORM1 was analyzed by methylation-specific PCR using methylation-specific primers designed for the ORM1 promoter region. Results: The serum levels of ORM1 in control group were found approximately 3.2 times higher compared to the patient group (p
Keywords: Artrit, romatoid; orosomukoid; DNA metilasyonu
- Hu X, Tang J, Hu X, Bao P, Deng W,Wu J, et al. Silencing of long non-coding RNA HOTTIP reduces inflammation in rheumatoidarthritis by demethylation of SFRP1. Mol Ther Nucleic Acids. 2020;6;19:468-81.[Crossref] [PubMed] [PMC]
- Haleagrahara N, Hodgson K,Miranda-Hernandez S, Hughes S, Kulur AB, Ketheesan N, et al. Flavonoidquercetin-methotrexate combination inhibits inflammatory mediators and matrixmetalloproteinase expression, providing protection to joints in collagen-induced arthritis.Inflammopharmacology. 2018;26(5):1219-32.[Crossref] [PubMed]
- Ciechomska M, Roszkowski L,Maslinski W. DNA Methylation as a future therapeutic and diagnostic target in rheumatoidarthritis. Cells. 2019;22;8(9):953.[Crossref] [PubMed] [PMC]
- Silman AJ, Pearson JE.Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4 Suppl 3(Suppl3):S265-72.[Crossref] [PubMed] [PMC]
- Aletaha D, Smolen JS. Diagnosisand management of rheumatoid arthritis: a review. JAMA. 2018;2;320(13):1360-72.[Crossref] [PubMed]
- Julià A, Absher D, López-LasantaM, Palau N, Pluma A, Waite Jones L, et al. Epigenome-wide association study of rheumatoidarthritis identifies differentially methylated loci in B cells. Hum Mol Genet.2017;15;26(14):2803-11.[Crossref] [PubMed]
- Bird A. Perceptions ofepigenetics. Nature. 2007;24;447(7143):396-8.[Crossref] [PubMed]
- Hua XM, Wang J, Qian DM, Song JY,Chen H, Zhu XL, et al. DNA methylation level of promoter region of activating transcriptionfactor 5 in glioma. J Zhejiang Univ Sci B. 2015;16(9):757-62.[Crossref] [PubMed] [PMC]
- Liu CC, Fang TJ, Ou TT, Wu CC, LiRN, Lin YC, et al. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoidarthritis. Immunol Lett. 2011;30;135(1-2):96-9.[Crossref] [PubMed]
- Ligresti G, Aplin AC, Dunn BE,Morishita A, Nicosia RF. The acute phase reactant orosomucoid-1 is a bimodal regulator ofangiogenesis with time- and context-dependent inhibitory and stimulatory properties. PLoSOne. 2012;7(8):e41387.[Crossref] [PubMed] [PMC]
- Cray C, Zaias J, Altman NH. Acute phase response in animals: a review.Comp Med. 2009;59(6):517-26.[PubMed] [PMC]
- Lin Y, Rajala MW, Berger JP,Moller DE, Barzilai N, Scherer PE, et al. Hyperglycemia-induced production of acute phasereactants in adipose tissue. J Biol Chem. 20019;276(45):42077-83.[Crossref] [PubMed]
- Lainé E, Couderc R,Roch-Arveiller M, Vasson MP, Giroud JP, Raichvarg D, et al. Modulation of humanpolymorphonuclear neutrophil functions by alpha 1-acid glycoprotein. Inflammation.1990;14(1):1-9.[Crossref] [PubMed]
- Smith KD, Pollacchi A, Field M,Watson J. The heterogeneity of the glycosylation of alpha-1-acid glycoprotein between thesera and synovial fluid in rheumatoid arthritis. Biomed Chromatogr. 2002;16(4):261-6.[Crossref] [PubMed]
- Aletaha D, Neogi T, Silman AJ,Funovits J, Felson DT, Clifton O, et al. 2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League against rheumatism collaborativeinitiative. Arthritis Rheum. 2010;62(9):2569-81.[Crossref] [PubMed]
- Ceciliani F, Pocacqua V. Theacute phase protein alpha1-acid glycoprotein: a model for altered glycosylation duringdiseases. Curr Protein Pept Sci. 2007;8(1):91-108.[Crossref] [PubMed]
- Hochepied T, Berger FG, BaumannH, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory andimmunomodulating properties. Cytokine Growth Factor Rev. 2003;14(1):25-34.[Crossref] [PubMed]
- Pepys MB, Hirschfield GM.C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-12.[Crossref] [PubMed] [PMC]
- Lacki JK, Porawska W, Mackiewicz SH, Muller W. Acute-phase response inearly refractory rheumatoid arthritis: long-term follow-up study. J Investig Allergol ClinImmunol. 1994;4(4):168-71.[PubMed]
- Hanada K, Yamanaka E, Yamamoto N,Minami H, Kawai S, Sasaki Y, et al. Effects of surgery and chronic disease states on theconcentrations and phenotype distribution of α1-acid glycoprotein: studies in patients withbreast cancer and patients with chronic inflammatory disease. Int J Clin Pharmacol Ther.2011;49(7):415-21.[Crossref] [PubMed]
- Gemelli C, Martello A, MontanariM, Zanocco Marani T, Salsi V, Zappavigna V, et al. The orosomucoid 1 protein is involved inthe vitamin D - mediated macrophage de-activation process. Exp Cell Res.2013;10;319(20):3201-13.[Crossref] [PubMed]
.: Process List